61 results
8-K
EX-99.1
BEAM
Beam Therapeutics Inc
7 May 24
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
7:09am
with BEAM-101 later this year. In addition, our team has done an incredible job executing our ex-U.S. clinical strategy for BEAM-302, securing CTA clearance
8-K
EX-99.1
BEAM
Beam Therapeutics Inc
8 Jan 24
Results of Operations and Financial Condition
6:55am
Wave 3: ~100,000 Beam’s multi-wave strategy is focused on developing safer, more effective, and more accessible treatments for patients with SCD
8-K
EX-99.2
7km0ih 0epchgip3wnd
8 Jan 24
Results of Operations and Financial Condition
6:55am
8-K
EX-99.1
30xe1n w20zzw
31 Oct 23
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
6:44am
8-K
qrwbzlw0ixdn xa
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am
8-K
EX-99.1
tn6guliyku
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am
8-K
EX-99.2
8lj6eoirqacop6yagts9
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am
8-K
EX-99.1
l5ysp93lkcd w7to5qfv
8 Aug 23
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
7:11am
8-K
EX-99.1
cuc sg0nzfko8s
10 May 23
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
7:00am
8-K
EX-99.1
zqfthvqypekuj1avr
7 Nov 22
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
7:00am
8-K
EX-99.1
rch0bo2
9 Aug 22
Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results
7:00am